|
注册号: Registration number: |
ChiCTR2600121523 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-31 17:09:35 |
|
注册时间: Date of Registration: |
2026-03-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
肿瘤患者放疗前癌因性疲乏发生率及相关影响因素:一项多中心的横断面调查研究 |
|
Public title: |
Cancer-Related Fatigue Incidence and Associated Influencing Factors in Cancer Patients Prior to Radiotherapy: A Multicenter Cross-Sectional Survey Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
肿瘤患者放疗前癌因性疲乏发生率及相关影响因素:一项多中心的横断面调查研究 |
|
Scientific title: |
Cancer-Related Fatigue Incidence and Associated Influencing Factors in Cancer Patients Prior to Radiotherapy: A Multicenter Cross-Sectional Survey Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
何东杰 |
研究负责人: |
邵秋菊 |
|
Applicant: |
hedongjie |
Study leader: |
shao qiuju |
|
申请注册联系人电话: Applicant telephone: |
+86 153 1976 5488 |
研究负责人电话:
Study leader's |
+86 189 9289 8513 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hedongjie20031129@163.com |
研究负责人电子邮件: Study leader's E-mail: |
shaoqj1966@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市灞桥区第四军医大学唐都医院放射治疗科 |
研究负责人通讯地址: |
陕西省西安市灞桥区第四军医大学唐都医院放射治疗科 |
|
Applicant address: |
Department of Radiation Oncology, Tangdu Hospital, Fourth Military Medical University, Baqiao District, Xi'an, Shaanxi Province, China |
Study leader's address: |
Department of Radiation Oncology, Tangdu Hospital, Fourth Military Medical University, Baqiao District, Xi'an, Shaanxi Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
710038 |
研究负责人邮政编码: Study leader's postcode: |
710038 |
|
申请人所在单位: |
中国人民解放军空军军医大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Air Force Medical University, Chinese People's Liberation Army |
||
|
研究负责人所在单位: |
中国人民解放军空军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Air Force Medical University, Chinese People's Liberation Army |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
第K202603-25号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
第四军医大学唐都医院药物临床试验机构伦理委员会 |
||
|
Name of the ethic committee: |
IEC of Institution for National Drug Clinical Trials, Tangdu Hospital, Fourth Military Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-16 00:00:00 | ||
|
伦理委员会联系人: |
李诗草 |
||
|
Contact Name of the ethic committee: |
li shicao |
||
|
伦理委员会联系地址: |
西安市灞桥区新寺路569号第四军医大学唐都医院药剂科办公楼304室 |
||
|
Contact Address of the ethic committee: |
Room 304, Pharmaceutical Affairs Office Building, Tangdu Hospital, Fourth Military Medical University, No. 569 Xinsi Road, Baqiao District, Xi'an 710038, Shaanxi Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 29 8477 7631 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
tangduec@126.com |
|
研究实施负责(组长)单位: |
中国人民解放军空军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Air Force Medical University, Chinese People's Liberation Army |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市灞桥区第四军医大学唐都医院放射治疗科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Department of Radiation Oncology, Tangdu Hospital, Fourth Military Medical University, Baqiao District, Xi'an, Shaanxi Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Tumor |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
调查接受根治性或辅助放疗的实体瘤患者,在放疗定位前癌因性疲乏的发生率及严重程度分布。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the incidence and severity distribution of cancer-related fatigue (CRF) in patients with solid tumors undergoing radical or adjuvant radiotherapy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.既往有颅脑放疗史或目前存在明确的脑转移瘤(以避免中枢神经系统直接受累对疲乏评估的混杂影响); 2.患有严重非癌性合并症,预期其本身可导致严重疲乏或显著干扰评估(如纽约心脏协会心功能分级IV级、严重慢性阻塞性肺疾病等); 3.正在参加其他以疲乏为主要终点的干预性临床试验; 4.研究者判断不适合参与本研究的任何其他情况; 5.存在认知障碍、语言沟通障碍或精神疾病,无法理解和完成问卷评估。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Prior history of cranial radiotherapy or presence of confirmed brain metastases (to avoid confounding effects of direct central nervous system involvement on fatigue assessment); 2.Severe non-malignant comorbidities expected to cause severe fatigue per se or significantly interfere with assessment (e.g., New York Heart Association Class IV heart failure, severe chronic obstructive pulmonary disease, etc.); 3.Currently enrolled in other interventional clinical trials with fatigue as the primary endpoint; 4.Any other conditions deemed by the investigators as unsuitable for participation in this study; 5.Cognitive impairment, language communication barriers, or psychiatric disorders that preclude understanding and completion of questionnaire assessment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-01 00:00:00至 To 2027-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-01 00:00:00 至 To 2027-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究使用和/或分析的数据集可在合理请求下向通讯作者获取,但须经伦理委员会批准,并符合患者隐私保护规定。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request, subject to the approval of the ethics committee and compliance with patient confidentiality protections. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质版病例报告表与Epidata或风锐EDC电子采集管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Paper-based Case Report Forms (CRFs) and Epidata or Electronic Data Capture (EDC) systems |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |